Event Summary
The 2009 Conference on Clinical Cancer Research, hosted by the Engelberg Center for Health Care Reform and Friends of Cancer Research, brought together distinguished members of the cancer community for in-depth discussions of critical issues at the intersection of clinical research and policy.
Event Information
When
Monday, September 14, 2009
8:30 AM to 4:30 PM
Where
Regency Ballroom
Hyatt Regency Hotel
400 New Jersey Avenue, NW
Washington, DC
Map
RELATED CONTENT
Tuesday, June 02, 2009
12:00 PM to 1:00 PM
Washington, DC
Joseph Antos, The Brookings Institution, September 29, 2009
More Related Content »
The all-day event on September 14 convened leaders from the National Cancer Institute (NCI), academia, patient advocacy organizations, the Food and Drug Administration (FDA), and various industry organizations, to discuss specific research and policy issues, as well as build consensus around solutions to critical questions regarding the future of clinical cancer research.
Opening remarks were delivered by NCI Director John Niederhuber, with keynote remarks offered by FDA Commissioner Margaret Hamburg. Interactive panel discussions focused on optimal data collection for clinical trials, development and approval of targeted therapies, and development of combination therapies targeting multiple pathways.
Participants
Panel 1: Data Submission Standards and Evidence Requirements
Moderator: Richard Schilsky
University of Chicago
Gwen Fyfe
Consultant
Jeffrey Abrams
National Cancer Institute
Robert Erwin
Marti Nelson Cancer Foundation
Robert Temple
Food and Drug Administration
Panel 2: Blinded Independent Central Review of PFS Endpoints
Moderator: Daniel Sargent
Mayo Clinic
Will Bushnell
GlaxoSmithKline
Ohad Amit
GlaxoSmithKline
Lori Dodd
National Institute of Allergy and Infectious Diseases
Nancy Roach
C3: Colorectal Cancer Coalition
Richard Padzur
Food and Drug Administration
Keynote Address
Welcome: Ellen Sigal
Friends of Cancer Research
Margaret Hamburg
Commissioner, Food and Drug Administration
Panel 3: Accelerating Development and Approval of Targeted Cancer Therapies
Moderator: David Kessler
University of California, San Francisco
Anna Barker
National Cancer Institute
David Epstein
Novartis
Stephen Friend
Sage Bionetworks
Cindy Geoghegan
Patient and Partners
David Sidransky
The Johns Hopkins University School of Medicine
Raymond Woosley
Critical Path Institute
Patricia Keegan
Food and Drug Administration
Panel 4: Development of Two Novel Therapeutics Targeting Multiple Pathways
Moderator: Charles Erlichman
Mayo Clinic
Adam Clark
Lance Armstrong Foundation
Matthew Ellis
Washington University in St. Louis
Stuart Lutzker
Genentech
James Zwiebel
National Cancer Institute
Janet Woodcock
Food and Drug Administration